Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Investment Rating - The investment rating for the pharmaceutical and biotechnology sector is "Outperform the Market" (maintained) [2] Core Insights - The pharmaceutical sector underperformed the market in Q4 2025, with the overall sector down by 9.3% compared to a slight decline of 0.2% in the CSI 300 index. Notably, the pharmaceutical commercial segment showed a positive performance with a 5.3% increase, while other segments like medical services and biological products experienced significant declines [4][8] - The total net asset value of pharmaceutical funds decreased to 358.4 billion yuan, a 9.0% decline quarter-on-quarter. This marks the first time since 2019 that passive pharmaceutical funds (181.8 billion yuan) surpassed active funds (176.5 billion yuan) [4][14] - The overall pharmaceutical holdings across all funds dropped to 7.97%, a decrease of 1.71 percentage points. Active pharmaceutical funds maintained a high concentration with a holding ratio of 97.45% [23] Summary by Sections 1. Market Review - In Q4 2025, the pharmaceutical and biotechnology sector lagged behind the CSI 300 index, with a decline of 9.3%. The chemical pharmaceuticals segment fell by 9.6%, biological products by 12.4%, and medical devices by 10.6% [8] 2. Pharmaceutical Fund Size - As of Q4 2025, the net asset value of pharmaceutical funds was 358.4 billion yuan, down 9.0% from the previous quarter. Active funds accounted for 176.5 billion yuan, a 14.6% decrease, while passive funds reached 181.8 billion yuan, down 2.8% [14] 3. Pharmaceutical Holdings Ratio - The pharmaceutical holdings ratio for all funds was 7.97%, down 1.71 percentage points. Active pharmaceutical funds had a holding ratio of 97.08%, while passive funds had 97.83% [23] 4. Holdings Structure Analysis - The highest sub-sector holding in Q4 2025 was chemical preparations at 37.5%, followed by other biological products at 20.8%. The largest increases in holdings were seen in traditional Chinese medicine (+0.98 percentage points) and chemical preparations (+0.62 percentage points) [29] 5. Additions and Reductions in Holdings - The top three pharmaceutical stocks by the number of funds holding them were Heng Rui Medicine (498 funds), WuXi AppTec (408 funds), and Mindray Medical (204 funds). Notably, Heng Rui Medicine saw a reduction of 236 funds, while Ying En Biological-B experienced an increase of 47 funds [84][88]

Group 1 - The Chinese government is advancing artificial intelligence (AI) technology innovation and application across various industries, highlighting its potential to transform production and lifestyle [2][3] - The government aims to establish a comprehensive AI ecosystem, focusing on algorithm innovation, high-quality data supply, and commercial applications to enhance AI's market presence [3] - The initiative includes promoting international cooperation and developing a robust governance framework for AI applications to ensure safety and compliance [3] Group 2 - The State Council of China has set a goal to establish a unified national electricity market by 2030, with market-based transactions accounting for approximately 70% of total electricity consumption [4] - The implementation plan includes 19 key tasks aimed at breaking down market barriers and encouraging participation from various stakeholders, including private enterprises [4] - This initiative is expected to enhance the efficiency of the energy sector and stabilize energy costs, thereby improving the global competitiveness of Chinese companies [4] Group 3 - The private equity sector shows optimism for the market, with over 62% of surveyed firms preferring to hold significant positions during the upcoming holiday, indicating confidence in structural opportunities despite market volatility [11] - The ETF market has seen a significant outflow of funds, with a 38.11% decrease in trading volume, while the total number of ETF shares increased by 1.68% [13] - The consumer sector in Hong Kong is experiencing a resurgence in IPO activity, with over 10 companies filing for H-shares in early 2026, indicating a growing interest in the market [14] Group 4 - The U.S. labor market showed unexpected growth in January, which may influence the Federal Reserve's interest rate decisions, suggesting a potential pause in rate hikes [15] - The technology sector is facing challenges, particularly in software stocks, as concerns about AI's impact on job functions and valuations continue to rise [6] - The cryptocurrency market experienced significant sell-offs, with Bitcoin dropping below $66,000, reflecting broader market volatility [6] Group 5 - Tianji Co. is under investigation by the China Securities Regulatory Commission for information disclosure violations, which may impact its operations [16] - The company has recently corrected financial reporting errors and is undergoing scrutiny for its governance practices [16] - The divorce settlement involving a major shareholder of a public company highlights the financial implications of personal matters on corporate governance [17] Group 6 - Wenta Technology announced that its control over Anshi Semiconductor remains limited due to ongoing investigations, affecting its operational strategy [19] - The company is facing challenges in its governance structure as it navigates legal and regulatory hurdles [19] - The semiconductor industry is under scrutiny, with companies like Wenta needing to adapt to changing regulatory environments [19]

Industry News - DeepSeek has updated its web and app versions to support a maximum context length of 1 million tokens, an increase from the previous 128K tokens in version 3.1 released last August [3] - The chief scientist of the China Automotive Technology and Research Center announced that the draft for GB/T "Solid-State Batteries for Electric Vehicles Part 1: Terminology and Classification" will be completed by December 2025, with a public consultation period ending on February 28, 2026 [3] - According to central bank data, by the end of 2025, the Shanghai Composite Index is expected to close at 3968.8 points, an increase of 18.4% from the end of 2024, while the Shenzhen Component Index is projected to reach 13525.0 points, up 29.9% [3] - The international oil prices have recently shown an upward trend, with significant premiums observed in oil funds. South Fund has adjusted the purchase limit for its oil fund to 1 yuan [3] - In January 2026, China's automotive industry maintained stable operations, with production and sales reaching 2.45 million and 2.346 million units respectively, with production increasing by 0.01% year-on-year and sales decreasing by 3.2% [4] Company News - Zhongji Xuchuang stated on its interactive platform that CSP customers place orders directly with the company, with no middlemen involved [5] - Giant Lifting announced that it has not signed a 4.58 billion project in Hainan, and its total orders in the commercial aerospace sector for 2025 amount to 9.9651 million yuan [6] - NetEase reported an operating profit of 35.8 billion yuan for 2025, representing a year-on-year increase of 21% [6] - Tianqi Mould announced plans to acquire 60% of Dongshi shares, and its stock has resumed trading [6] - The company Kaiying Network signed a settlement agreement with the legendary IP, which is expected to have a positive impact of approximately 200 million yuan on its current profits [12] - Newray announced plans to acquire 70% of PCB tool company Hui Lian Electronics for no more than 700 million yuan [12] - Longbai Group plans to acquire 5.46% of Yunnan Guotai's shares for 234 million yuan [12] - Dazhi Technology announced that its Zhangbei data center project will not involve computing power leasing business [12]

Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. has participated in the continuation procurement of drugs whose agreements have expired under the national organization procurement program, with 13 products proposed for selection in this round [1][2]. Group 1: Proposed Selected Products - The proposed selected products include 12 that were previously selected in the first to eighth batches of the national organization procurement, and one new product, Paricalcitol Injection [2]. - The total expected sales revenue from these products is approximately 651.20 million yuan for 2024, accounting for 48.25% of the company's total revenue for that year [2]. - For the first nine months of 2025, the expected sales revenue is about 504.08 million yuan, representing 49.46% of the company's total revenue for that period [2]. Group 2: Impact on the Company - The procurement cycle for these selected products will run from the actual execution date of the selection results until December 31, 2028, with medical institutions prioritizing the use of these selected drugs [2]. - The overall procurement is expected to maintain price stability or further decline, providing medical institutions with greater choice and ensuring continuity in clinical medication [2]. - Although some selected products may see a decrease in price compared to previous sales, having 13 products proposed for selection allows the company to solidify its market share and enhance the accessibility of these drugs [2].

Investment Rating - The industry investment rating is "Overweight (Maintain)" [4] Core Insights - The recent results of the national centralized procurement for batches 1-8 have been released, which is expected to benefit leading companies with scale effects, particularly those integrated in raw material and formulation production [6] - The procurement process involved 5.1 million medical institutions and 1,091 domestic and foreign companies, with 4,163 products selected from 1,020 companies, indicating a high participation rate and a stable supply of selected products [6] - The procurement cycle is set to last until the end of 2028, allowing selected companies to secure a three-year national market, which is beneficial for capacity planning and cost optimization [6] Summary by Sections Industry Overview - The industry comprises 502 listed companies with a total market value of 73,023.15 billion yuan and a circulating market value of 67,026.08 billion yuan [2] Procurement Results - The procurement covers 316 commonly used drugs across 26 therapeutic areas, with a high selection rate of 93% for participating companies [6] - The average number of selected companies per product is 14, ensuring a diverse supply base and rich clinical choices [6] Competitive Landscape - The procurement reflects a shift in policy from "price reduction and expansion" to "price stability and quality assurance," favoring leading companies with compliance capabilities and scale advantages [6] - Companies like Huahai Pharmaceutical and Kelun Pharmaceutical have significant advantages in their respective fields, with high selection rates for major products [6] Future Outlook - The procurement process is expected to stabilize prices and industry expectations, moving the focus from "lowest price competition" to a comprehensive competition based on quality, capacity, compliance, and brand [6] - The new requirements for production experience and compliance are likely to accelerate the exit of smaller, weaker companies from the market [6]

Core Viewpoint - The company, Yuandong Biotech (688513.SH), has participated in the procurement process for the continuation of drug products after the expiration of the national organized procurement agreements, with 13 products, including Bisoprolol Fumarate Tablets and Etoricoxib Tablets, proposed for selection in this procurement [1] Group 1 - The procurement process is led by Jiangsu, Henan, and Guangdong provinces, aiming to stabilize or further reduce prices while providing greater choice for medical institutions [1] - The selection of products allows medical institutions to choose suppliers with better supply assurance capabilities, thereby ensuring continuity in clinical medication and reducing the risks associated with drug switching due to centralized procurement [1] - Although some selected products have lower prices compared to previous sales, the selection of 13 products positions the company to maintain its market share and enhance the accessibility of these drugs if contracts are signed and executed [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) has participated in the procurement process for the continuation of drug selection following the expiration of the national organized procurement agreements, with 13 products, including Fumarate Bisoprolol Tablets and Etoricoxib Tablets, proposed for selection in this round of procurement [1] Group 1 - The procurement process is organized by Jiangsu, Henan, and Guangdong provinces, aiming to stabilize or further reduce drug prices while providing greater choice for medical institutions [1] - The selection of 13 products by the company, despite some price reductions compared to original sales prices, is expected to help maintain market share and enhance drug accessibility if contracts are signed and executed [1] - The procurement aims to ensure continuity in clinical medication and reduce the risks associated with drug switching due to organized procurement [1]

Group 1 - Unisplendour Corporation has decided to terminate its plan to issue H-shares and list on the Hong Kong Stock Exchange due to strategic development considerations [2] - Yuandong Biotech is participating in a follow-up procurement for 13 products, with expected sales revenue of approximately 651 million yuan in 2024, accounting for 48.25% of total revenue [3] - Blue Lithium has terminated its participation in the GreenMei Indonesia project due to strategic adjustments by GreenMei, with no significant impact on its operations [4] Group 2 - Jinhaitong plans to invest up to 400 million yuan in the construction of a semiconductor equipment manufacturing center in Shanghai, covering an area of 55,000 square meters [5] - Kaiying Network's subsidiary has signed a settlement agreement with Legend IP, which is expected to positively impact profits by approximately 200 million yuan [6] - Newray plans to acquire 70% of PCB tool company Huilian Electronics for no more than 700 million yuan, enhancing its market position in the PCB tool sector [7] Group 3 - Longbai Group intends to acquire a 5.46% stake in Yunnan Guotai for 234 million yuan [8] - Dawi Technology's Zhangbei data center project is set to be completed by October 2025, primarily providing customized standard data center environments [9] Group 4 - Guobang Electronics reported a net profit of 508 million yuan for 2025, a year-on-year increase of 4.72%, despite a revenue decline of 7.92% [11] - Daotong Technology achieved a net profit of 935 million yuan in 2025, reflecting a significant year-on-year growth of 45.89% [12] - Jingchen Co. reported a net profit of 871 million yuan for 2025, with a growth of 6% year-on-year [13] Group 5 - Qizhou Dongfeng plans to repurchase shares worth between 50 million and 100 million yuan to implement an employee stock ownership plan [17] - Keri Technology's shareholders plan to reduce their holdings by a total of up to 3.13% of the company's shares [19] Group 6 - Roman Co. signed a 260 million yuan contract for a wind power project, with the company’s share of the contract amounting to approximately 190 million yuan [21] - Zhongke Haixun is expected to win projects totaling approximately 288 million yuan [22] - Shan Jian Co. won four construction projects with a total value of 4.834 billion yuan [23]

证券代码：688513 证券简称：苑东生物 公告编号：2026-004 成都苑东生物制药股份有限公司 关于自愿披露公司参与国家组织集采药品协议期满 品种接续采购拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，成都苑东生物制药股份有限公司（以下简称"公司"）参与了由江苏省、 河南省和广东省牵头组织的原国家组织集采1-8批协议期满品种接续采购的申报 工作。根据国家组织集采药品协议期满品种接续采购办公室（以下简称"接续采 购办公室"）于 2026 年 2 月 10 日在广东省医疗保障局官网（http://hsa.gd.gov.cn） 发布的《国家组织集采药品协议期满品种接续采购拟中选结果公示》显示，公司 富马酸比索洛尔片、依托考昔片等 13 个产品拟中选本次接续采购。现将相关情 况公告如下： 一、拟中选产品基本情况 | 序号 | 拟中选品 | | 适应症或功能主治 | 主要规格包 | 拟中选 | 采购 | 拟中选 | | --- | --- | --- | --- | --- | --- | --- | -- ...